Latest breakthroughs in cancer research, treatment, and prevention
602 articoli
Uno studio di fase 3 rileva che somministrare l'immunochemioterapia prima delle 13:00 quasi raddoppia la sopravvivenza libera da progressione e la sopravvivenza globale nei pazienti con NSCLC.
Il ginsenoside Rh4 sopprime il cancro del colon-retto potenziando *Akkermansia muciniphila* ed elevando l'acido biliare protettivo UDCA attraverso la segnalazione FXR.
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer — blocking it supercharges immunotherapy response.
A counterintuitive mechanism shows that more NECTIN4 antigen on tumor cells can actually blunt antibody-drug conjugate therapy.
Tumor-infiltrating adipocytes release a lipid metabolite that triggers neutrophil cell death, suppressing CD8+ T cells in pancreatic cancer.
A Nature Medicine study finds pathogenic germline variants in pediatric patients signal elevated cancer risk, reshaping early genetic screening protocols.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
Circulating tumor DNA testing alongside primary treatment may sharpen prognosis for men with metastatic prostate cancer.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
